Pneumococcal conjugate vaccine, 20-valent

PBAC's latest decision on Pneumococcal conjugate vaccine, 20-valent: Recommended (2023). Considered for Prevention of pneumococcal disease caused by Streptococcus pneumoniae in paediatric populations including infants aged 12 months or younger and children with NIP-funded risk conditions.

Eligible population

Children aged 12 months or younger in NSW, VIC, ACT, and TAS and non-Indigenous children aged 12 months or younger in QLD, NT, WA and SA (2+1 schedule); Aboriginal and Torres Strait Islander children aged 12 months or younger in QLD, NT, WA and SA (3+1 schedule); children aged 12 months or younger with NIP-funded risk conditions (3+1 schedule); children aged more than 12 months with NIP-funded risk conditions (single dose)

Therapy area

Vaccines

Line of therapy

Not applicable

Evidence base

RCT

Primary endpoint

Other

Comparator

13-valent pneumococcal conjugate vaccine (13vPCV) and 15-valent pneumococcal conjugate vaccine (15vPCV)

Economic model

Cost-minimisation

ICER note

Cost-minimisation approach used; no ICER calculated by design

Similar precedents

• Pneumococcal polysaccharide conjugate vaccine, 20-valent
  similarity 0.91
• Pneumococcal polysaccharide conjugate 13-valent
  similarity 0.82
• Pneumococcal conjugate vaccine 13-valent (13vpcv) and pneumococcal polysaccharide vaccine 23-valent (23vppv)
  similarity 0.82
• Pneumococcal conjugate vaccine, 15-valent
  similarity 0.81
• Pneumococcal polysaccharide conjugate vaccine, 13-valent
  similarity 0.80
• Pneumococcal conjugate vaccine, 13-valent
  similarity 0.78